Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
Authors' conclusion
S-TKIs permitted tailoring systemic treatment based on disease location, tumour volume and patient comorbidities, achieving satisfactory tolerance and outcomes in selected patients with an actionable driver mutation and with contraindications to angiogenesis inhibitors or candidates for redifferentiation therapy.
Study context
- Population
- Patients with advanced RAI-refractory thyroid cancer treated with TKIs as first-line treatment, Federico II University Hospital, September 2016 to September 202444 treated with first-line TKIs
- Participants
- 31 / 13 / 8 / 2 / 3
- Exposure
- Lenvatinib vs selective TKIs as first-line therapy
- Lenvatinibn = 31
- Selective tyrosine kinase inhibitors (s-TKIs)n = 13
- Dabrafenib + trametinib (DT)n = 8
- Selpercatinibn = 2
- DT redifferentiationn = 3
- Outcome
- RECIST partial response
Methodological detailssingle-centre, consecutive patients, outside any clinical trial
- Single-centre
- Consecutive patients
- Outside any clinical trial
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| PFS rate · 1 year | Lenvatinib 72% · DT 69% |
| Overall survival rate · 1 year | Lenvatinib 83% · DT 83% |
| PFS at data cut-offBoth selpercatinib-treated patients | Selpercatinib 10 months |
Treatment-related deaths
- Treatment-related deaths
- 0
Safety
Grade ≥3 adverse events
Original publication
Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer? Eur Thyroid J. Published 22 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →